aluates Reports

$ 0.0

Automative

Global APOL1 Mediated Kidney Disease Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-9Y10149

Global APOL1 Mediated Kidney Disease Market Insights Forecast to 2028

BUY CHAPTERS

Global APOL1 Mediated Kidney Disease Market Research Report 2025

Code: QYRE-Auto-9Y10149

Report

July 2025

Pages:75

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Vertex Pharmaceuticals

Ionis Pharmaceuticals

ChemoCentryx Inc

GlaxoSmithKline PLC

Novartis

Teva Pharmaceuticals

Travere Therapeutics

ZyVersa Therapeutics

APOL1 Mediated Kidney Disease Market Size

The global market for APOL1 Mediated Kidney Disease was valued at US$ 905 million in the year 2024 and is projected to reach a revised size of US$ 1354 million by 2031, growing at a CAGR of 6.0% during the forecast period.

APOL1 Mediated Kidney Disease Market

APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for APOL1 Mediated Kidney Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding APOL1 Mediated Kidney Disease.

The APOL1 Mediated Kidney Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global APOL1 Mediated Kidney Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the APOL1 Mediated Kidney Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of APOL1 Mediated Kidney Disease Market Report

Report Metric	Details
Report Name	APOL1 Mediated Kidney Disease Market
Accounted market size in year	US$ 905 million
Forecasted market size in 2031	US$ 1354 million
CAGR	6.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Small Molecule Gene Modification Nucleic Acid Therapies Others
Segment by Application	Chronic Kidney Disease End Stage Kidney Disease
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis, Teva Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is APOL1 Mediated Kidney Disease Market growing?

Ans: The APOL1 Mediated Kidney Disease Market witnessing a CAGR of 6.0% during the forecast period 2025-2031.

What is the APOL1 Mediated Kidney Disease Market size in 2031?

Ans: The APOL1 Mediated Kidney Disease Market size in 2031 will be US$ 1354 million.

Who are the main players in the APOL1 Mediated Kidney Disease Market report?

Ans: The main players in the APOL1 Mediated Kidney Disease Market are Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis, Teva Pharmaceuticals

What are the Application segmentation covered in the APOL1 Mediated Kidney Disease Market report?

Ans: The Applications covered in the APOL1 Mediated Kidney Disease Market report are Chronic Kidney Disease, End Stage Kidney Disease

What are the Type segmentation covered in the APOL1 Mediated Kidney Disease Market report?

Ans: The Types covered in the APOL1 Mediated Kidney Disease Market report are Small Molecule, Gene Modification, Nucleic Acid Therapies, Others

Recommended Reports

Kidney Disease Markets

Genetic & Autoimmune

Renal and Related Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Small Molecule

1.2.3 Gene Modification

1.2.4 Nucleic Acid Therapies

1.2.5 Others

1.3 Market by Application

1.3.1 Global APOL1 Mediated Kidney Disease Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Chronic Kidney Disease

1.3.3 End Stage Kidney Disease

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global APOL1 Mediated Kidney Disease Market Perspective (2020-2031)

2.2 Global APOL1 Mediated Kidney Disease Growth Trends by Region

2.2.1 Global APOL1 Mediated Kidney Disease Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 APOL1 Mediated Kidney Disease Historic Market Size by Region (2020-2025)

2.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2026-2031)

2.3 APOL1 Mediated Kidney Disease Market Dynamics

2.3.1 APOL1 Mediated Kidney Disease Industry Trends

2.3.2 APOL1 Mediated Kidney Disease Market Drivers

2.3.3 APOL1 Mediated Kidney Disease Market Challenges

2.3.4 APOL1 Mediated Kidney Disease Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue

3.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2020-2025)

3.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2020-2025)

3.2 Global APOL1 Mediated Kidney Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by APOL1 Mediated Kidney Disease Revenue

3.4 Global APOL1 Mediated Kidney Disease Market Concentration Ratio

3.4.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2024

3.5 Global Key Players of APOL1 Mediated Kidney Disease Head office and Area Served

3.6 Global Key Players of APOL1 Mediated Kidney Disease, Product and Application

3.7 Global Key Players of APOL1 Mediated Kidney Disease, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 APOL1 Mediated Kidney Disease Breakdown Data by Type

4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2020-2025)

4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2026-2031)

5 APOL1 Mediated Kidney Disease Breakdown Data by Application

5.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2020-2025)

5.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America APOL1 Mediated Kidney Disease Market Size (2020-2031)

6.2 North America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)

6.4 North America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe APOL1 Mediated Kidney Disease Market Size (2020-2031)

7.2 Europe APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)

7.4 Europe APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2020-2031)

8.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2020-2025)

8.4 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America APOL1 Mediated Kidney Disease Market Size (2020-2031)

9.2 Latin America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)

9.4 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2020-2031)

10.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)

10.4 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Vertex Pharmaceuticals

11.1.1 Vertex Pharmaceuticals Company Details

11.1.2 Vertex Pharmaceuticals Business Overview

11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction

11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.1.5 Vertex Pharmaceuticals Recent Development

11.2 Ionis Pharmaceuticals

11.2.1 Ionis Pharmaceuticals Company Details

11.2.2 Ionis Pharmaceuticals Business Overview

11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction

11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.2.5 Ionis Pharmaceuticals Recent Development

11.3 Travere Therapeutics

11.3.1 Travere Therapeutics Company Details

11.3.2 Travere Therapeutics Business Overview

11.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Introduction

11.3.4 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.3.5 Travere Therapeutics Recent Development

11.4 ChemoCentryx

11.4.1 ChemoCentryx Company Details

11.4.2 ChemoCentryx Business Overview

11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction

11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.4.5 ChemoCentryx Recent Development

11.5 ZyVersa Therapeutics

11.5.1 ZyVersa Therapeutics Company Details

11.5.2 ZyVersa Therapeutics Business Overview

11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction

11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.5.5 ZyVersa Therapeutics Recent Development

11.6 GlaxoSmithKline

11.6.1 GlaxoSmithKline Company Details

11.6.2 GlaxoSmithKline Business Overview

11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction

11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.6.5 GlaxoSmithKline Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction

11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.7.5 Novartis Recent Development

11.8 Teva Pharmaceuticals

11.8.1 Teva Pharmaceuticals Company Details

11.8.2 Teva Pharmaceuticals Business Overview

11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction

11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)

11.8.5 Teva Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Vertex Pharmaceuticals

Ionis Pharmaceuticals

ChemoCentryx Inc

GlaxoSmithKline PLC

Novartis

Teva Pharmaceuticals

Travere Therapeutics

ZyVersa Therapeutics

List of Tables

Table 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Small Molecule

Table 3. Key Players of Gene Modification

Table 4. Key Players of Nucleic Acid Therapies

Table 5. Key Players of Others

Table 6. Global APOL1 Mediated Kidney Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global APOL1 Mediated Kidney Disease Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global APOL1 Mediated Kidney Disease Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global APOL1 Mediated Kidney Disease Market Share by Region (2020-2025)

Table 10. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global APOL1 Mediated Kidney Disease Market Share by Region (2026-2031)

Table 12. APOL1 Mediated Kidney Disease Market Trends

Table 13. APOL1 Mediated Kidney Disease Market Drivers

Table 14. APOL1 Mediated Kidney Disease Market Challenges

Table 15. APOL1 Mediated Kidney Disease Market Restraints

Table 16. Global APOL1 Mediated Kidney Disease Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global APOL1 Mediated Kidney Disease Market Share by Players (2020-2025)

Table 18. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2024)

Table 19. Ranking of Global Top APOL1 Mediated Kidney Disease Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by APOL1 Mediated Kidney Disease Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of APOL1 Mediated Kidney Disease, Headquarters and Area Served

Table 22. Global Key Players of APOL1 Mediated Kidney Disease, Product and Application

Table 23. Global Key Players of APOL1 Mediated Kidney Disease, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global APOL1 Mediated Kidney Disease Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2020-2025)

Table 27. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2026-2031)

Table 29. Global APOL1 Mediated Kidney Disease Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2020-2025)

Table 31. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2026-2031)

Table 33. North America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific APOL1 Mediated Kidney Disease Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)

Table 48. Vertex Pharmaceuticals Company Details

Table 49. Vertex Pharmaceuticals Business Overview

Table 50. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 51. Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 52. Vertex Pharmaceuticals Recent Development

Table 53. Ionis Pharmaceuticals Company Details

Table 54. Ionis Pharmaceuticals Business Overview

Table 55. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 56. Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 57. Ionis Pharmaceuticals Recent Development

Table 58. Travere Therapeutics Company Details

Table 59. Travere Therapeutics Business Overview

Table 60. Travere Therapeutics APOL1 Mediated Kidney Disease Product

Table 61. Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 62. Travere Therapeutics Recent Development

Table 63. ChemoCentryx Company Details

Table 64. ChemoCentryx Business Overview

Table 65. ChemoCentryx APOL1 Mediated Kidney Disease Product

Table 66. ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 67. ChemoCentryx Recent Development

Table 68. ZyVersa Therapeutics Company Details

Table 69. ZyVersa Therapeutics Business Overview

Table 70. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product

Table 71. ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 72. ZyVersa Therapeutics Recent Development

Table 73. GlaxoSmithKline Company Details

Table 74. GlaxoSmithKline Business Overview

Table 75. GlaxoSmithKline APOL1 Mediated Kidney Disease Product

Table 76. GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 77. GlaxoSmithKline Recent Development

Table 78. Novartis Company Details

Table 79. Novartis Business Overview

Table 80. Novartis APOL1 Mediated Kidney Disease Product

Table 81. Novartis Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 82. Novartis Recent Development

Table 83. Teva Pharmaceuticals Company Details

Table 84. Teva Pharmaceuticals Business Overview

Table 85. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 86. Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)

Table 87. Teva Pharmaceuticals Recent Development

Table 88. Research Programs/Design for This Report

Table 89. Key Data Information from Secondary Sources

Table 90. Key Data Information from Primary Sources

Table 91. Authors List of This Report

List of Figures

Figure 1. APOL1 Mediated Kidney Disease Picture

Figure 2. Global APOL1 Mediated Kidney Disease Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global APOL1 Mediated Kidney Disease Market Share by Type: 2024 VS 2031

Figure 4. Small Molecule Features

Figure 5. Gene Modification Features

Figure 6. Nucleic Acid Therapies Features

Figure 7. Others Features

Figure 8. Global APOL1 Mediated Kidney Disease Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global APOL1 Mediated Kidney Disease Market Share by Application: 2024 VS 2031

Figure 10. Chronic Kidney Disease Case Studies

Figure 11. End Stage Kidney Disease Case Studies

Figure 12. APOL1 Mediated Kidney Disease Report Years Considered

Figure 13. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global APOL1 Mediated Kidney Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global APOL1 Mediated Kidney Disease Market Share by Region: 2024 VS 2031

Figure 16. Global APOL1 Mediated Kidney Disease Market Share by Players in 2024

Figure 17. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by APOL1 Mediated Kidney Disease Revenue in 2024

Figure 19. North America APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)

Figure 21. United States APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)

Figure 25. Germany APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Region (2020-2031)

Figure 33. China APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)

Figure 41. Mexico APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)

Figure 45. Turkey APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Vertex Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 49. Ionis Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 50. Travere Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 51. ChemoCentryx Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 52. ZyVersa Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 53. GlaxoSmithKline Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 54. Novartis Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 55. Teva Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Renal Therapeutic Market Research Report 2025

Global Bartter Syndrome Treatment Market Research Report 2024

Global Renal Diseases Drug Market Insights Forecast to 2030

Global APO E Gene Test Kit Market Research Report 2025

Global APO E Gene Test Market Research Report 2025

Global Focal Nodular Glomerulosclerosis FSGS Treatment Medicine Market Research Report 2025

Global Apolipoprotein E Genotype Test Kit Market Research Report 2025

Global Bartter Syndrome Drugs Market Research Report 2024

Global End Stage Kidney Disease Market Research Report 2024

Global Focal Glomerular Sclerosis FSGS Treatment Medicine Market Research Report 2025

Kidney Machines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chronic Kidney Disease Medication Market Research Report 2024

Global End Stage Renal Disease Market Research Report 2024

Renal Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global MUC1 ELISA Kits Market Research Report 2024

Kidney Renal Fibrosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gene Knockdown Stable Cell Line Service Market Research Report 2024

Sphingosine 1 Receptor Modulators Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Alport Syndrome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0I20198

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-33W11115

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32E19705

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions